Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retapamulin 1% ointment vs oral linezolid for MRSA secondarily infected traumatic lesions and impetigo
2015-004886-98Phase 3
- Sponsor
- GSK
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in traumatic wound, impetigo and Staphylococcus aureus infection comparing Retapamulin arm with Linezolid arm (2 arms). Primary endpoint: Clinical response at follow-up.
02
Drugs
retapamulinlinezolid
03
Conditions
traumatic woundimpetigoStaphylococcus aureus infection
Beyond the preview
Go deeper on 2015-004886-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004886-98.